ASP Isotopes (NASDAQ:ASPI – Get Free Report) will likely be releasing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect ASP Isotopes to post earnings of ($0.1367) per share and revenue of $2.0310 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.
ASP Isotopes Price Performance
NASDAQ:ASPI opened at $4.37 on Friday. ASP Isotopes has a 12-month low of $3.92 and a 12-month high of $14.49. The firm has a market cap of $484.37 million, a price-to-earnings ratio of -3.36 and a beta of 3.55. The company’s 50-day moving average is $5.78 and its two-hundred day moving average is $7.27. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04.
Insider Transactions at ASP Isotopes
In related news, COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $5.44, for a total value of $45,902.72. Following the transaction, the chief operating officer owned 1,537,817 shares in the company, valued at approximately $8,365,724.48. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 14.40% of the company’s stock.
Institutional Investors Weigh In On ASP Isotopes
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on ASPI shares. Cantor Fitzgerald began coverage on shares of ASP Isotopes in a research report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $13.00.
Read Our Latest Report on ASP Isotopes
ASP Isotopes Company Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Featured Stories
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
